Latest Derivatives News

BlackRock Investment Management has announced an estimated distribution of 317.02 cents per unit for the iShares Asia 50 ETF for the period ending June 30, 2025, with a detailed breakdown of income sources and tax components.

BlackRock Investment Management has announced an estimated 26.3 cents per unit cash distribution for its iShares Core FTSE Global Property Ex Australia ETF for the period ending June 30, 2025. The distribution is composed entirely of non-assessable income, with no dividends or capital gains included.

Betashares Capital Ltd has released the estimated annual distribution components for its Global Shares Currency Hedged ETF (HGBL) for the 2024-25 financial year, highlighting a nuanced mix of foreign income and capital gains.

Betashares Capital Ltd has disclosed the estimated annual distribution components for its Global Banks Currency Hedged ETF (ASX, BNKS) for the fiscal year ending June 2025, highlighting a significant foreign income portion and a full cash payout.

Gold Mountain Limited reports promising high-grade rare earth element anomalies and new gold targets at its Varzedo Prospect in Brazil, advancing its Down Under Rare Earths Project.

BPH Global has launched a focused R&D collaboration with Temasek Polytechnic to develop seaweed-based bio-stimulants aimed at boosting growth and yields in Southeast Asia's oil palm and rice sectors. Early talks are also underway for a production facility in Indonesia to commercialize these innovations.

Cosmo Metals reveals striking historical gold assay results from the Mt Ephraim deep-lead mine within its Nundle Project, spotlighting a promising new target for large-scale gold-copper mineralisation in New South Wales.

Saturn Metals has reported a new zone of thick, high-grade gold intersections at its Apollo Hill project, significantly enhancing its exploration potential. The newly defined 'Iris Zone' shows promising mineralisation open along strike and down plunge.

Santana Minerals has unveiled an updated Pre-Feasibility Study for its Bendigo-Ophir Gold Project, revealing lower capital costs, higher gold grades, and robust financial returns that position the project as a low-cost, high-margin operation in New Zealand.

Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.

State Street Global Advisors has announced a 21.5897 cents per unit cash distribution for the SPDR S&P/ASX Small Ordinaries ETF for the period ending June 30, 2025, alongside franking and foreign tax credits.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.